Intraocular (Uveal) melanoma - Pipeline Insight, 2021

Intraocular (Uveal) melanoma - Pipeline Insight, 2021

  • March 2021 •
  • 120 pages •
  • Report ID: 6034118 •
  • Format: PDF
“Intraocular (Uveal) melanoma – Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Intraocular(Uveal) melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Intraocular (Uveal) melanoma Understanding

Intraocular (Uveal) melanoma: Overview
Uveal melanoma is the most common primary intraocular malignancy in adults. Intraocular is a disease in which malignant cells form in the tissues of the eye. Signs of intraocular melanoma include blurred vision or a dark spot on the iris. While development of uveal melanoma is largely considered to be a sporadic event, certain risk factors including light iris color, light skin color, ability to tan and others predispose individuals to Uveal melanoma. Tests that examine the eye are: Ophthalmoscopy, Slip-lamp examination, Gonioscopy and others have been used to help diagnose intraocular melanoma. A biopsy of the tumor is very rarely needed to diagnose intraocular melanoma. The treatment options include: Surgery, Thermotherapy, Radiation therapy, Coagulation.

"Intraocular(Uveal) melanoma - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Wilson’s Disease pipeline landscape is provided which includes the disease overview and Intraocular(Uveal) melanoma treatment guidelines. The assessment part of the report embraces, in depth Intraocular (Uveal) melanoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Intraocular(Uveal) melanoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
? The companies and academics are working to assess challenges and seek opportunities that could influence Intraocular (Uveal) melanoma R&D. The therapies under development are focused on novel approaches to treat/improve Intraocular (Uveal) melanoma.

Intraocular (Uveal) melanoma Emerging Drugs Chapters
This segment of the Intraocular (Uveal) melanoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Intraocular (Uveal) melanoma Emerging Drugs
? BVD-523: BioMed Valley Discoveries, Inc
BVD-523 (ulixertinib), a novel targeted cytotoxic designed to inhibit ERK, can be used to treat cancers that harbor mutations in the MAPK signaling pathway. BVD-523, either alone or in combination with other drugs, will be a valuable strategy to safely treat cancers that exhibit abnormal MAPK pathway activity. BVD-523 clinical trials are being evaluated in phase II stage of development for the treatment of Uveal Melanoma.

? AU-011: Aura Biosciences, Inc
AU-011 is being studied in phase II stage for the treatment of Uveal melanoma. Administration of AU-011 into the SC space (SCS) has potential benefits, including significantly higher concentration of drug in the tumor, which may improve certain treatment parameters. The drug has been granted Orphan drug designation and Fast track designation by U.S Food and Drug Administration.

? PAC-1: Vanquish Oncology
Procaspase Activating Compound-1 (PAC-1) is being evaluated in phase I/II stage for the treatment of Uveal Melanoma. PAC-1 is a apoptotic stimulant and Caspase 3 stimulant that acts as a central trigger point in the apoptotic pathway and is aberrantly elevated in many cancer types and when activated induces cancer cell death.
Further product details are provided in the report……..

Intraocular(Uveal) melanoma: Therapeutic Assessment
This segment of the report provides insights about the different Intraocular (Uveal) melanoma drugs segregated based on following parameters that define the scope of the report, such as:
? Major Players in Intraocular(Uveal) melanoma
There are approx. 15+ key companies which are developing the therapies for Intraocular (Uveal) melanoma. The companies which have their Intraocular (Uveal) melanoma drug candidates in the most advanced stage, i.e. phase II include BioMed Valley Discoveries, Inc,.

? Phases
This report covers around 15+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

? Route of Administration
Intraocular(Uveal) melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Subcutaneous
• Intravenous
• Intramuscular

? Molecule Type
Products have been categorized under various Molecule types such as
• Bispecific Antibody
• Peptides
• Small molecule
• Gene therapy
? Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Intraocular(Uveal) melanoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Intraocular (Uveal) melanoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Intraocular (Uveal) melanoma drugs.

Intraocular(Uveal) melanoma Report Insights
• Intraocular(Uveal) melanoma Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Intraocular(Uveal) melanoma Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Intraocular(Uveal) melanoma drugs?
• How many Intraocular(Uveal) melanoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Intraocular(Uveal) melanoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Intraocular(Uveal) melanoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Intraocular(Uveal) melanoma and their status?
• What are the key designations that have been granted to the emerging drugs?